PRGL493


Catalog No. Size PriceQuantity
M24811-C Contact sales@xcessbio.com for quotation $100

Description

PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research.

Product information

CAS Number: 2479378-45-3

Molecular Weight: 451.48

Formula: C25H21N7O2

Chemical Name: N-{13-[3-(5-methylfuran-2-yl)-1-phenyl-1H-pyrazol-4-yl]-1,8,10,12-tetraazatricyclo[7.4.0.0²,⁷]trideca-2,4,6,8,11-pentaen-11-yl}acetamide

Smiles: CC1=CC=C(O1)C1=NN(C=C1C1N=C(NC2=NC3=CC=CC=C3N21)NC(C)=O)C1C=CC=CC=1

InChiKey: QNWGOBIYAPLFMK-UHFFFAOYSA-N

InChi: InChI=1S/C25H21N7O2/c1-15-12-13-21(34-15)22-18(14-31(30-22)17-8-4-3-5-9-17)23-28-24(26-16(2)33)29-25-27-19-10-6-7-11-20(19)32(23)25/h3-14,23H,1-2H3,(H2,26,27,28,29,33)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 5 mg/mL (11.07 mM; ultrasonic and warming and heat to 60°C).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Acyl-CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme-A family taking part in arachidonic acid metabolism and steroidogenesis. PRGL493 ([3H]-AA (0.5 µCi/ml in serumfree medium) for 3 h; 48 hours) signifcantly inhibits the activity of ACSL4 in all three cell lines (MDA-MB-231, PC-3 and MA-10 Leydig cells), as evidenced by a reduction in AA-CoA levels.But PRGL493 has no effects on ACSL4 protein expression. PRGL493 (20-100 μM; 72 hours) inhibits the proliferation of highly aggressive breast and prostate cancer cells at an IC50 of 23 µM and 27 µM, respectively.

In Vivo:

PRGL493 (intraperitoneal injection; 250 μg/Kg; 43 and 34 consecutive days) decreases tumor volumes and inhibits tumor growth. Additionally, this compound results in a decrease in Ki67 protein expression and increases ER and AR expression in breast and prostate xenograft tumors, respectively.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed